A B S T R A C T Subsequent to studies indicating that cholecystographic agents and sulfobromophthalein (BSP) inhibit uptake of thyroxine (T4) by rat liver slices, the effect of such compounds on hepatic storage of T, in man has been examined. After intravenous administration of [1'251]T4 to five normal subjects, hepatic radioactivity, estimated by external gamma counting, rose to a peak in -4 h and then declined in parallel with serum radioactivity. When a 6-g dose of the cholecystographic agent, tyropanoate (Bilopaque), was administered orally 3 d later, estimated hepatic extravasctilar radioactivity fell 50-60% within 4 h and then rose toward the pretyropanoate value. Concomitant with the fall in hepatic radioactivity, serum radioactivity rose 57-70%, as did stable T4 levels in serum, suggesting that hormone discharged from the liver entered the serum. Both uptake ofT4 and discharge by tyropanoate were much less in two patients with liver disease.
INTRODUCTION
It was once thought that iodine-containing radiographic contrast agents affect thyroid function chiefly by releasing inorganic iodide. However, two drugs employed for oral cholecystography, iopanoate (Telepa(ue, Winthrop Laboratories, N. Y.) and ipodate (Oragrafin, E. R. Squibb & Sons, Princeton, N. J.), are now known to cause a major decline in circulating levels of the potent thyroid hormone triiodothyronine (T3)1 by virtue of their ability to inhibit peripheral conversion of thyroxine (T4) to T3 (1, 2) . Cholecystographic agents also inhibit conversion of T4 to T3 in vitro (3) (4) (5) .
Yet another effect ofiopanoate and ipodate on thyroid hormone economy has recently been demonstrated in our laboratory, namely, their ability to inhibit uptake of T4 and T3 by rat liver slices; similar effects were produced by sulfobromophthalein (BSP) and bilinibin (4) . The findings suggested that the agents might be able to discharge thyroid hormones from the liver in vivo. To study this possibility in man, we chose the agent sodium tyropanoate (Bilopaque, Winthrop Laboratories) because Suzuki et al.,2 in comparing the effect of various agents on hormone levels, found that this drug provoked an acute and significant increase in serum T4. Our results indicate that a major discharge of T4 from the liver follows tyropanoate ingestion; ipodate and BSP cause a similar but less striking discharge.
METHODS
Subjects. Five healthy volunteers were studied: three white men and two white women (Table I ). All had normal ' Abbreviations used in this paper: BSP, sulfobromophthalein; ISF, interstitial fluid, RIA, radioimmunoassav; T3, triiodothyronine; T4, thyroxine. 2 The following work was published after manuscript was written: Suzuki, H., N. Kadena, K. Takeushi, and S. Nakagawa. Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-thyroid axis. Acta Enidocrinol. After -72 h, long enough for hepatic and serum counts to reach a steady state of decline, a 6-g dose of sodium tyropanoate was administered orally; liver counting and blood sampling continued for another 24-48 h. The patient was fasting on the morming of drug administration to promote more rapid absorption of the gallbladder agent; the fast was ended 4 h after drug ingestion.
4-7 d after tyropanoate administration, when liver:serum 1251 ratios had stabilized near their original level, three subjects were given BSP intravenously, 5 mg/kg on one day and 20 mg/kg on the following day. Serial liver counts and blood specimens were obtained as in the standard protocol.
Two volunteers were retested with ipodate. The protocol was identical except that the dose of ipodate was 12 rather than 6 g. One subject was also retested using a 3-g and later a 9-g dose of tyropanoate.
External counting over the liver. Subjects were studied at two hospitals; at one the detector has a 2-in. sodium iodide crystal and at the other a 3-in. crystal. Gamma energies from 20 to 65 keV were couinted and were corrected for room background. Using a point source of 1251 in a water bath, the half-thickness value for both probes was 0.75 cm, i.e., the count rate decreased 50% for each 0.75-cm distance in water from the crystal. Because of this limited range, heavy collimation to block out radioactivity from distant perihepatic tissues seemed unnecessary, and most subjects were studied without a collimator, applying the detector directly to the chest wall. The limited range did mean, however, that chest wall tissues could make a significant contribution to net count rates. Assuming a chest wall thickness of 2.5 cm, and an "infinite" thickness of liver beyond, chest wall tissues would be counted at about eight times the efficiency of the liver and could contribute 10% to net counts even though the relative isotope concentrations in liver and chest wall were 50:1. Although the major conclusions of the present study are not compromised by this factor, a correction for chest wall activity would be necessary for precise quantitation of hepatic 1251 content. The chest wall factor would be less, employing 131I- Special analyses on serum. Tvo additional procedures wvere used to determine the nature of the increased serum radioactivity produced by tyropanoate. First, a serum sample obtained from one subject at the peak of the tyropanoate effect was subjected to column chromatography on Sephadex G-25, using a technique previously described (6) . Second, serumii samples obtained from subject 5 just before tyropanoate and also at the peak of the tyropanoate effect were subjected to precipitation with trichloroacetic acid (TCA), uising a modification of the technique of Lepp et al. (7) . After initial counting, 0.125 ml serum was mixed with 1.75 ml distilled H20; 0.5 ml of 40% TCA was then added. After mixing, the tube wvas centrifuged for 20 min at 2,000 rpm, the suipernate decanted, and the tube recounted.
Serum samples from the ipodate studies wvere also subjected to equilibrium dialysis to determine the free T4 fraction, using the technique of Sterling and Brenner (8) . 3 Analysis of data. Data analvsis wvas similar to that of Cavalieri and Searle (9) . L(t) is the count rate over the liver at time (t) after T4 injection, normalized to a value of 100 at t = 0. Similarly, S(t) is the count rate per unit volume of serum or plasma, normiialized to 100 at t = 0. Count rates at t = 0 were estimated by extrapolation of the early portions of the hepatic uptake and serum disappearance curves, respectivelv. It is assumed that L(0) is the result ofradioactivity in the hepatic vascular space seen by the probe, and that the contribution of hepatic intravascular counts to total liver counts at any later time t can be estimated as L(0) x S(t)/S(0), or, because L(0) and S(0) are both normalized to 100, simply as S(t). Therefore, a ratio L(t):S(t) > 1.0 implies entrv of tracer into the hepatic extravascular space, anid the difference, L(t) -S(t), should be directly proportional to the hepatic extravascular radioactivity. Also, the percent change in hepatic extravascular T4 content between any two times, t, and t2, can be expressed as
Effects of tyropanoate. Fig. 1 shows the results of the complete study in subject 3. There was a rapid initial uptake of hormone by the liver, reaching a maxinum--4 h after injection. Hepatic and serum 1251 then gradually declined over the next 72 h, approximately in parallel. When tyropanoate was given, a prompt fall in hepatic radioactivity ensued, reaching a nadir -4 h later. There was a marked rise in the serum radioactivity at the same time that hepatic radioactivity fell, thus providing strong evidence that tyropanoate causes a discharge into the circulation of thyroxine stored within the liver. Over the next 48 h, both liver and serum radioactivity returned toward values that would have been predicted had the drug not been administered, suggesting that the effect is reversible. This is consistent with tyropanoate's relatively brief biologic halflife, being rapidly excreted into bile and then removed in the feces (10) .
The results in each of the five normal subjects were similar to those depicted in Fig ministration of tyropanoate, the ratio fell in 2-4 h to a nadir that varied from 2.8 to 5.3. Fig. 3 shows all five subjects plotted together, with the values for liver: serum ratios having been normalized to a value of 1.0 at the time of tyropanoate administration. Expressed in this manner, there was a remarkable uniformity in the pattern of decline in the liver:serum ratios. Also shown in this figure is the result in one subject who was retested with 3-and 9-g doses of tyropanoate; the change in liver:serum ratios was roughly proportional to dosage. In conjuction with the 9-g dose, serial counts were made over the left lower quadrant of the abdomen and over the right and left upper chest. In each site, concomitant with the rise in serum 1251 content and the fall in count rate over the liver, tyropanoate administration was followed by a rise in the count rate.
In the serum sample obtained at the peak of the tyropanoate effect, and subjected to column chro- The liver:serum ratio at the time of tyropanoate administration has been normalized to a value of 1.0. The results in one subject who was restudied with 3-and 9-g doses oftyropanoate are shown by the light and heavy dashed lines, respectively. matography, 90% of the radioactivity migrated in the expected location of T4. This is confirmation that the radioactivity discharged from the liver is T4 rather than a metabolic breakdown product. The results obtained by TCA precipitation provide additional confirmation. In a control sample of serum, to which a known amount of ['251]T4 had been added, 90% of the radioactivity was precipitated with TCA. In a serum sample drawn just before giving tyropanoate, the value was 92%, and in two samples taken near the peak of tyropanoate's effect, the values were 89 and 93%. This is evidence that breakdown of T4 to iodide is not a major part of the response to tyropanoate administration.
The pattern of change in hepatic extravascular radioactivity (A[L -S], defined in Methods) and in serum radioactivity in the five studies with 6 g tyropanoate is shown in Fig. 4 . The proportionate change in serum radioactivity exceeded that in the liver, suggesting that the amount discharged was a smaller proportion of hepatic radioactivity than of serum radioactivity. Serum radioactivity also peaked first, suggesting that egress from serum to nonhepatic sites occurred and equalled the rate of ingress from liver 2-3 h after tyropanoate ingestion. If all the radioactivity leaving the liver enters the serum, the ratio between the changes in serum and hepatic radioactivity, at an early time point before significant 125I has left the serum for nonhepatic sites, should equal the ratio between the hepatic T4 distribution volume and the plasma volume. In the two patients with liver disease, hepatic T4 uptake, as judged by liver:serum 1251 ratios, was much less than in the normal subjects (Fig. 2) (20) (21) (22) , dog (23) , and manl (24) . maller than the Lichter et al. (25) (26) , and were found in all species tested, including rats, mice, guinea pigs, rhesus monkeys, sheep, and man. Lichter et al. (25) were able to show that both T4 and T3 are bound by both Y and Z, i important role and are displaced from these proteins by BSP and by s. Cavalieri and bilirubin. However, there was prominent binding of patic pool of T4 the thyroid hormones to other cytosol proteins; the iges in the level major portion of T4 was bound to a protein (or proteins) have shown that migrating near, but distinct from, albumin on Sephadex hormone occur G-100. BSP and bilirubin displaced T4 from this protein gs. Nicoloff and as well as from Y and Z. Dillman et al. (22) also ) have reported described a rat liver cytosol protein that could bind T4, T4 is increased and that had an affinity for BSP about 1:10,000 of that for T4; the ratio of BSP to T4 in the displacement studies by Lichter et al. (25) may have been in the same range. Although Davis et al. (23) , in their study of canine liver cytosol proteins, did not see prominent binding of BSP to the cytosol T4-binding protein, they did not specifically study the ability of large amounts of BSP to displace T4 from its specific protein.
Thus, the available evidence suggests that high concentrations of the organic anions, BSP and bilirubin, caan displace T4 from binding to cytosol proteins, even though the major protein involved may not be the Y or Z protein. Our own studies in liver slices (4) have shown that cholecystographic agents, including tyropanoate and ipodate, share with BSP and bilirubin the ability to displace T4 from cells. The interaction of organic anions with hepatic T4 binding proteins may be weak in man, as it is in rats; the molar ratio between our standard dose oftyropanoate (6 g, 9.0 mmol) and an estimate of hepatic T4 content (270 gg, 0.35 ,imol) is in the neighborhood of 25,000:1. The effective dose of BSP, 20 mg/kg, would represent -2 *nmol, yielding a BSP:T4 ratio of 6,000:1.
In addition to cytosol binding proteins, it is possible that plasma membrane transport plays a role in the accumnulation of cholecystographic agents and T4 by hepatocytes. Scharschmidt et al. (27) have demonstrated in the rat that there is a carrier-membrane transport system for the hepatic uptake of organic anions such as BSP, bilirubin, and indocyanine green. The agents are mutually competitive ligands for this process. Receptors for BSP have been identified in liver plasma membranes (28) . Pliam and Goldfine (29) have demonstrated specific thyroid hormone binding sites in rat liver plasma membranes. It seems conceivable, therefore, that competitive inhibition of inward transport through the plasma membrane is another mechanism of tyropanoate's effects; to explain discharge of accumulated hormone by this mechanism would also require that exit from the cell be less inhibited than entrv, and that exit be fairly rapid.
The two possible mechanisms have quite different implications for the intracellular fate of T4. If cholecystographic agents interfere primarily with membrane tranisport, this could result in a lowering of intracellular free T4 levels. On the other hand, if the primary effect is to inhibit binding of T4 already within the cell to cytosol proteins, cholecystographic agents shouild transiently increase the intracellular free T4 levels. Further study is clearly indicated to sort through these possibilities and to determine the effect of gallb)ladder agents uipon intracellular free T4 levels.
Our data in patients with liver disease, although limited, suggest that the dischargeable hepatic T4 pool was almost abolished. Also, there was a slower rate of initial e(quilibration betwveen count rates over the liver ancd serumiii 1251 concenltration (Fig. 2) ; this may reflect uptake into chest wall tissues that accumulate T4 at the slow rate characteristic of the arm (30), leg (9, 17) , or muscle tissue in general (31) .
It has previously been shown that a major effect of cholecystographic agents is to block the peripheral conversion ofT4 to T3 (1) (2) (3) (4) (5) , an effect shared by tyropanoate.2 Indeed, Wu et al. (32) have used repeated doses of ipodate in the treatment of hyperthyroidism. A decreased hepatic uptake of T4 is one potential mechanism for decreased T3 formation; Jennings et al. (33) have recently suggested that decreased hepatic uptake of T4, rather than decreased activity of a converting enzyme, is responsible for the decreased rate of T3 production that occurs in fasting. However, when the time-course we have demonstrated for tyropanoate's effect on hepatic T4 content (maximum at 4 h, dissipated by 24 h) is compared with that for inhibition of T3 formation (persisting beyond 3 d2), it seems likely that the two effects are separate.
There has been disagreement in the literature concerning the magnitude of the hepatic storage pool for thyroid hormones. Nicoloff and Dowling (30) calculated that the liver represents about 14% of the total nonthyroidal pool of T4; a similar estimate was made by Busnardo et al. (13) . Cavalieri and Searle, however, reported values twice as large for this pool, claiming that nearly one-third of the total nonthyroidal pool of T4 is located in the liver (9, 17) . The figure offered by Oppenheimer et al. (14) is in close agreement; they report that 29% of the total extrathyroidal pool is in the liver, and similar values are given by some other workers (15, 16) .
Further support for the larger hepatic pool size derives from extensive studies performed both in sheep (34, 35) and in man (36) by Irvine, who concludes that the liver contributes 30% of the total pool of extrathyroidal T4 in man (31) . The smaller estimates derive from models in which the interstitial fluid (ISF) is viewed as a separately equilibrating compartment, whose size is estimated by the early passage of radioactivity into the arm (30) or thigh (13) . Irvine has, however, demonstrated that the rate of change in the specific activity of lymph in animals injected with labeled hormone varies from organ to organ, so that the ISF specific activity in each organ is about the same as the total tissue specific activity (35), i.e., transfer of T4 from plasma to ISF is the rate-limiting step in tissue entry. This negates the assumption by Nicoloff and Dowling (12) of a distinct ISF pool; moreover, their assumption that the liver has an ISF compartment corresponding to the early change in arm:plasma count rate ratios results in assigning a large component of hepatic T4 to the interstitial space. Evidence that the hepatic interstitial T4 pool is small has been provided in autoradiographic studies by Oppenheimer et al. (14, 37) and in direct postmortem measurements of hepatic interstitial T4 in sheep where the ratio, hepatic ISF T4:hepatic plasma T4, was <0.2 (34) . Expressing the data of Cavalieri and Searle (9, 17), Oppenheimer (14) , and Irvine (31) (Table II) , is higher. Because there were no evident errors in our estimation ofplasma radioactivity, the major error that could elevate the ratio would be an underestimate of the proportion of radioactivity discharged from the liver (A[L -SI in Table II ). It is possible that the segment of liver counted is not representative, and that portions of the liver distant from the probe discharge more completely; there is no noninvasive method to check this possibility, although gamma camera images ofthe liver, performed in subject 2, showed a uniform loss of 1251 after tyropanoate. A more well-defined source of error is the contribution of chest wall radioactivity to "liver" counts. In one subject, placing the probe over the upper chest gave a count rate about one-tenth that over the liver, before tyropanoate ingestion. Using this value to correct for the chest wall contribution in each subject, the mean value for A(L -S) in Table II (38) and cytosol binding proteins for cholecystographic agents (39) similar to those found in liver, and has been shown to concentrate T4 in man (37) . Assuming that the renal pool is one-sixth the size of the hepatic pool, this would further reduce the estimate ofthe liver space alone to 1.4 times the plasma volume, more closely agreeing with earlier workers. It does seem unlikely that other tissues are responsible for much of T4 discharge. Counting over the upper chest, there was actually a rise in radioactivity after tyropanoate; in studies not reported here, we have observed similar increases in radioactivity over the arm and thigh after tyropanoate ingestion. In each site, the rise has been compatible with the rise in plasma radioactivity, and there was little net change in extravascular radioactivity in the chest wall, arm, or thigh. In other words, tyropanoate did not appear to cause significant discharge of T4 from skeletal muscle, the major repository of extravascular T4 beside liver and kidney (31) .
There are other possible errors in our method that could lead to an underestimate of the hepatic T4 space. First, tyropanoate could discharge 1251 into bile so that 4Green, W. L., and G. Bellamy. Unpublished observations. only a portion of T4 lost from the liver entered serum.
Also, from the nature of the curve in Fig. 6 , it seems likely that some of the 1251 entering serum from liver had already been lost to other extravascular sites by 1 h, and that ratios computed at earlier time intervals would have been higher and would more accurately reflect relative distribution volumes. It is of course possible that estimates in the literature are low. In particular, some of the values for plasma volume reported by Cavalieri and Searle (9, 17) and by Oppenheimer et al. (14) seem large.
The only agent previously shown to displace labeled T4 from the liver (40) with a concomitant rise in serum radioactivity (40, 41) is diethyl ether; a similar redistribution of T4 may be caused by halothane (42) and isoflurane (43) . The published data concerning the effects of ether anesthesia on radioactivity in serum, liver, and thigh in subjects who had received [131I]T4 60 h earlier (40) can be interpreted as showing some discharge from the thigh as well as the liver,5 in contrast to tyropanoate which does not discharge T4 from the thigh. We speculate, therefore, that the effect of ether has a different mechanism than the effect of tyropanoate, and, thus, that the present studies may be the first example in man of a direct effect on hepatic T4 content. Agents inhibiting hepatic storage of T4 may provide a useful tool for investigating the effects of disease and physiologic variables on hepatic storage. From considerations discussed above, our standard protocol provides an approximate estimate of the distribution volume ratio between liver and serum. This method could be applied, for example, to determine whether fasting alters hepatic storage of T4 in man, as it apparently does in rats (33) . thigh counts represent intravascular radioactivity, the failure of thigh counts to change when serum radioactivity rose implies some loss ofextravascular radioactivity from the thigh; substituting thigh radioactivity for liver radioactivity in Eq. 1, and assuming that 30% of initial thigh radioactivity was intravascular, the data of Oyama et al. (40) indicate a 25% decline in thigh extravascular T4 content during anesthesia. A firm conclusion cannot be reached, however, because ether may also cause changes in regional blood flow and in plasma volume. Using labeled human serum albumin, we have shown in two subjects that tyropanoate does not alter plasma volume, nor the amount ofexternally detected labeled albumin in liver and thigh.
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